11 March 2022
Latham & Watkins Advises on Travere’s Upsized US$275 Million Convertible Senior Notes Offering
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Cheston Larson Lead | Latham & Watkins LLP | Partner | corporate | San Diego |
| Matthew Bush Lead | Latham & Watkins LLP | Partner | corporate | San Diego |
| Anthony Gostanian | Latham & Watkins LLP | Counsel | corporate | San Diego |
| Rachel Staub | Latham & Watkins LLP | Associate | corporate | San Diego |
| Giannina Marciano | Latham & Watkins LLP | Associate | corporate | San Diego |
| Greg Rodgers | Latham & Watkins LLP | Partner | convertible debt | New York |
| Arash Aminian Baghai | Latham & Watkins LLP | Partner | convertible debt | Los Angeles |
| Steven Schmulenson | Latham & Watkins LLP | Associate | convertible debt | Los Angeles |
| Bora Bozkurt | Latham & Watkins LLP | Partner | tax | New York |
Stated terms
- Stated value
- USD 275m (US$275 million)
- What the figure measures
- Issue size
- Client
- Travere Therapeutics, Inc.Issuer
- Counterparties
- underwriters (Underwriters)